Newer FDA approvals semaglutide for cardiovascular risk reduction, tirzepatide for obstructive sleep apnea are gradually widening what Medicare and commercial plans will pay for, and they are sometimes the only route to coverage where a weight-loss exclusion applies
What stands out is that retatrutide, still in phase 3 trials, is already drawing generic interest
Novo Nordisk sells it as Victoza for diabetes and as Saxenda at a higher dose for obesity
Orskov, C., Wettergren, A
Dietary fibre may mitigate sarcopenia risk: findings from the NU-AGE Cohort of older European adults
Obes Surg 27(2):513521 Peng MG, Gokoffski KK (2021) Updates on recent Developments in Idiopathic Intracranial Hypertension